Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer

Phase 2positivedivesiranPositive

AI Analysis

Summary

Silence Therapeutics' siRNA drug divesiran met its primary endpoint in Phase 2 trials for polycythemia vera, enabling advancement to Phase 3 development.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Met primary endpoint

Importance:7/10

Sentiment:

0.85

gene-silencingsiRNArare diseasehematologyphase progression

Related Companies

$VERA

Read the original article

Published by Endpoints News on August 10, 2026 11:31 AM

Read Original